+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
536565 NOVELIX

Novelix Pharmaceuticals Share Price

 

 

Novelix Pharmaceuticals live price: ₹83.7. It opened at ₹80 vs previous close ₹79; intraday high/low: ₹85/₹77. The 50 & 200 DMA stand at ₹59.50/₹52.20.

Novelix Pharmaceuticals Performance

  • Today's Low
  • ₹77
  • Today's High
  • ₹85
  • 52 Week Low
  • ₹29
  • 52 Week High
  • ₹85
  • Open Price₹80
  • Previous Close₹79
  • Volume23,263
  • 50 DMA₹59.50
  • 100 DMA₹57.36
  • 200 DMA₹52.20

Novelix Pharmaceuticals Chart

Investment Returns

  • Over 1 Month + 54.63%
  • Over 3 Month + 47.72%
  • Over 6 Month + 43.84%
  • Over 1 Year + 185.37%

Smart Investing Starts Here Start SIP with Novelix Pharmaceuticals for Steady Growth!

Invest Now

Novelix Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 57.7
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 147
  • P/B Ratio
  • 3.4
  • Average True Range
  • 6.27
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • 3.09
  • RSI
  • 85.77
  • MFI
  • 95.39

Novelix Pharmaceuticals Financials

Novelix Pharmaceuticals Technicals

EMA & SMA

Current Price
₹83.70
+ 4.22 (5.31%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹64.40
  • 50 Day
  • ₹59.50
  • 100 Day
  • ₹57.40
  • 200 Day
  • ₹52.20

Resistance and Support

81.34 Pivot Speed
  • R3 93.98
  • R2 89.34
  • R1 85.98
  • S1 77.98
  • S2 73.34
  • S3 69.98

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Novelix Pharmaceuticals Ltd has an operating revenue of Rs. 132.31 Cr. on a trailing 12-month basis. An annual revenue growth of 331% is outstanding, Pre-tax margin of 3% needs improvement, ROE of 5% is fair but needs improvement. The company has a reasonable debt to equity of 9%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 40% and 47% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 13% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 71 which is a FAIR score but needs to improve its earnings, a RS Rating of 96 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 95 indicates it belongs to a poor industry group of Food-Packaged and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Novelix Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-06-04 Preferential Issue of shares & Others Inter-alia, to consider 1. Approve the Draft Notice of EGM. 2.Fix the day, date, time & venue of EGM. 3. Appoint Scrutinizer for conducting E- voting process for EGM. 4. Other business matters.
2026-05-29 Audited Results & Preferential issue
2026-02-12 Quarterly Results
2025-11-13 Quarterly Results
2025-08-14 Quarterly Results & A.G.M.

Novelix Pharmaceuticals Shareholding Pattern

50.57%
45.8%
3.63%

Novelix Pharmaceuticals FAQs

Novelix Pharmaceuticals share price is ₹83 As on 15 June, 2026 | 00:03

The Market Cap of Novelix Pharmaceuticals is ₹147.4 Cr As on 15 June, 2026 | 00:03

The P/E ratio of Novelix Pharmaceuticals is 57.7 As on 15 June, 2026 | 00:03

The PB ratio of Novelix Pharmaceuticals is 3.4 As on 15 June, 2026 | 00:03

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23